Skip to main content

Estudio del papel de la inflamación periférica en el continuo esclerosis lateral amiotrófica/demencia frontotemporal a resolución celular

PI24/01087

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2024
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO INSTITUT DE RECERCA HOSPITAL DE LA SANTA CREU I SANT PAU
Execution centre INSTITUT DE RECERCA SANT PAU

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Novel Splicing Variant in Atypical Presentation of Familial Frontotemporal Lobar Degeneration

  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Bernal, Sara|||0000-0003-4427-0574
  • Almenta Gallego, David|||0000-0001-9069-8948
  • Perez Blanco, Josefina|||0000-0002-6489-8871
  • Camacho, Valle|||0000-0003-0748-0847
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
C-truncating variants in the charged multivesicular body protein 2B (CHMP2B) gene are a rare cause of frontotemporal lobar degeneration (FTLD), previously identified only in Denmark, Belgium, and China. We report a novel CHMP2B splice-site variant (c.35-1G>A) associated with familial FTLD in Spain. The cases were two monozygotic male twins who presented at ages 62 and 66 years with a slowly progressive behavioral variant of frontotemporal dementia and a syndrome mimicking dementia with Lewy bodies, respectively. Functional and in silico analyses supported the pathogenicity of this variant. Our findings contribute new insights into the genetic landscape and clinical heterogeneity of FTLD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old

  • Ceriello, Chiara
  • Torres Bonafonte, Olga H.|||0000-0002-0305-8211
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Vera-Campuzano, Elena
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • Lorente, Oriol
  • Carreras, Mireia
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Belbin, Olivia|||0000-0002-6109-6371
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
Background and Objectives: Alzheimer disease (AD) is increasingly viewed as a clinical-biological continuum, but the utility of biomarkers in individuals aged ≥80 years, the so-called “very old,” remains uncertain, because of concerns about its clinical usefulness. This study aimed to determine the clinical impact and prognostic value of AD biomarkers in very old individuals. Methods: We performed a retrospective longitudinal cohort study within the Sant Pau Initiative on Neurodegeneration (SPIN, Barcelona, Spain), a memory clinic–based research cohort. Patients were referred from primary care physicians or community neurologists for evaluation within a public universal health care catchment area. We included SPIN participants evaluated between October 2013 and May 2024 who were aged ≥80 years and had mild cognitive impairment (MCI) at the baseline visit. Participants underwent standardized clinical and neuropsychological assessments and had CSF and plasma biomarker measurements available. AD biology was defined by the CSF phosphorylated tau at threonine 181/amyloid-β 42 ratio. Plasma phosphorylated tau at threonine 217 (p-Tau217) was evaluated for (1) diagnostic accuracy for AD biology and (2) prognostic associations with longitudinal cognitive change (Mini-Mental State Examination [MMSE]) and progression to dementia. Analyses used linear mixed-effects models for MMSE trajectories and Cox regression for dementia conversion. Results: A total of 167 participants were included (mean age 82.3 years, 59% women) with a mean follow-up of 35.8 months; the ones with AD biology (n = 116, 69%) had worse baseline cognitive performance, particularly in memory, compared with those without (Cohen d = 0.34, p = 0.03). Plasma p-Tau217 showed excellent diagnostic accuracy for detecting AD biology (0.93, 95% CI 0.88–0.98; cutoff 0.19 pg/mL; sensitivity 94.5%; specificity 84%). Over time, participants with AD biology declined faster on the MMSE than those without (−0.47 vs −0.18 points per year; p < 0.01). Cox models showed an increased risk of progression to a dementia stage among individuals with higher plasma p-Tau217 concentrations (hazard ratio 1.49, 95% CI 1.05–2.13, p = 0.026). Discussion: In very old individuals with MCI, AD biology (CSF) and plasma p-Tau217 identify individuals at higher risk of faster cognitive decline and progression to dementia. Limitations of this study include the single-center design and the modest sample size.